USPTO serial 99446868
XYNAPSE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 11, 2026
- Examiner
- MORRIS, ALINA S.
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with XYNAPSE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Miriam D. Trudell
Miriam D. Trudell Davis Graham & Stubbs LLP3400 Walnut Street, Suite 700Denver, CO 80205United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products for diagnostic, industrial and scientific purposes, namely reagents and assays for activation, stimulation and proliferation of immune cells T cells and B cells, other than for medical or veterinary use; Diagnostic reagents for diagnostic and scientific purposes, other than for medical or veterinary use; Research reagents for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic test materials in the nature of reagents and assays for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic kits comprising diagnostic agents, preparations and substances for scientific and diagnostic purposes, other than for medical or veterinary use; Assays for research and diagnostic purposes, other than for medical or veterinary use; Biochemical reagents, other than for medical or veterinary use; Analytical preparations in the nature of reagents and assays for scientific purposes related to research and development of vaccines and immunotherapeutics, cancer vaccines, borrelia vaccines, tuberculosis vaccines, HIV vaccines, CMV vaccines and other vaccines, or for use in connection with research and development of drug therapy and immunotherapy, including cancer therapy, cancer immunotherapy, for scientific analysis of pharmaceuticals for T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and for analysis of pharmaceuticals infectious diseases and autoimmunity, and for scientific and research use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring, other than for medical or veterinary use; Chemical reagents for diagnostic, industrial and scientific purposes | ACTIVE | — |
| 005 | Preparations for pharmaceutical purposes, for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Preparations for medical purposes, namely, diagnostic preparations for medical purposes and medical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Chemical-pharmaceutical preparations for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Diagnostic preparations for medical purposes; Reagents for medical and veterinary purposes; Vaccines; Analytical preparations in the nature of assays and reagents for medical purposes, including for the medical or diagnostic analysis of vaccines, immunotherapeutics and cellular therapy, including cancer vaccines and immunotherapeutics, borrelia vaccines, tuberculosis vaccines, HIV vaccines and CMV vaccines, T-cell treatments, or for use in connection with cancer therapy or other therapy, for the diagnosis or treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and infectious diseases, and for use in connection with medical or diagnostic analysis of toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 11, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 11, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 23, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 23, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 17, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 29, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 28, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 28, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 28, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 11, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 4, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 16, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 16, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 16, 2025 | NWAP | NEW APPLICATION ENTERED | — |